RECEPTOR.AI
The AI engine Fit Assessment
BetaReceptor.AI leverages machine learning and AI technologies to discover new drug candidates and expand therapeutics, optimizing the drug discovery process.
Blurb
RECEPTOR.AI - drug discovery for precision medecine
HQ Location
London (United Kingdom)
Founded
2021
Employees
11 - 50
Total funding raised
$500.00K
Last Funding Event
Grant, December 1, 2022
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Drug Discovery Optimization
Developer of AI-powered drug discovery platform designed to identify novel targets and design drug candidates with high success rates in clinical trials. The company is focused on providing an AI-driven drug discovery platform for pharma, biotech, and academia that covers the whole drug discovery pipeline in a flexible and scalable manner, thereby enabling an increase in precision of drug candidate design and the quality of their assessment and target specificity.